GOVERNMENT PERFORMANCE AND RESULTS ACT (GPRA)

PROGRAM INSTRUMENT FOR
STATE OPIOID RESPONSE (SOR) AND TRIBAL OPIOID RESPONSE (TOR)
DISCRETIONARY GRANT PROGRAMS

QUESTION-BY-QUESTION INSTRUCTION GUIDE

June 2019
Version 1.0
Program Instrument Questions

The program instrument for State Opioid Response (SOR) and Tribal Opioid Response (TOR) contains a total of three questions, and it should be reported by program staff every quarter.

Reporting quarters are as follows:

Q1: October 1–December 31; reporting due January 31
Q2: January 1–March 30; reporting due April 30
Q3: April 1–June 30; reporting due July 31
Q4: July 1–September 30; reporting due October 31

1. Has your state/territory/tribal entity used SOR/TOR funds to expand the availability, distribution, and use of naloxone overdose reversal kits (Narcan, Evzio, and others)?

Naloxone overdose reversal kits include the following:

- **Narcan®**: Naloxone Hydrochloride U.S. Food and Drug Administration (FDA)-approved nasal spray used for the treatment of an opioid emergency.
- **Evzio®**: Naloxone Hydrochloride FDA-approved auto-injector used for the treatment of an opioid emergency.

Other generic brands of injectable naloxone are offered by various companies, including Mylan, West-Ward, and Aurum.

If the response is “Yes,” continue to question 1a.

If the response is “No,” skip questions 1a and 1b; the program instrument is complete.

1a. If “Yes,” how many naloxone overdose reversal kits have been purchased (funded) wholly or in part since the last reporting period with SOR/TOR funds?

If the response to question 1 was “Yes,” your program has “used SOR/TOR funds to expand the availability, distribution, and use of naloxone overdose reversal kits,” please enter the number of kits purchased wholly or in part with SOR/TOR funding since the last reporting period.

If you are not able to report the number of kits purchased, select one of the codes listed below to indicate why this information is unavailable:

1. DATA UNAVAILABLE
2. DATA AVAILABLE, BUT UNABLE TO OBTAIN IN ALLOTTED TIME
3. DATA AVAILABLE, BUT INCONSISTENT IN DIFFERENT DATA SOURCES
4. OTHER

This question should be skipped if the response to question 1 was “No.”
1b. If “Yes,” how many naloxone overdose reversal kits funded wholly or in part by SOR/TOR funds have been distributed since the last reporting period?

If the response to question 1 was “Yes,” your program has “used SOR/TOR funds to expand the availability, distribution, and use of naloxone overdose reversal kits,” please enter the number of kits funded wholly or in part with SOR/TOR funds that have been distributed since the last reporting period.

If you are not able to report the number of kits distributed, select one of the codes listed below to indicate why this information is not available:

1. DATA UNAVAILABLE
2. DATA AVAILABLE, BUT UNABLE TO OBTAIN IN ALLOTTED TIME
3. DATA AVAILABLE, BUT INCONSISTENT IN DIFFERENT DATA SOURCES
4. OTHER

This question should be skipped if the response to question 1 was “No.”

This is the last question. The program instrument is now complete.